Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

Strong financial position supports clinical focus on advancing drug

candidates for treatment of lysosomal storage disorders

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the first quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.34 per share ($0.28 per share on a non-GAAP basis) for the three months ended March 31, 2008. As of March 31, 2008, cash, cash equivalents, and marketable securities totaled $154.6 million.

"In the first quarter of 2008, we continued to advance our three lead clinical development programs. We also reported data from multiple clinical trials that add to the growing body of evidence demonstrating that treatment with our oral pharmacological chaperone drug candidates has the potential to benefit patients with Fabry, Gaucher and Pompe disease," said John F. Crowley, President and CEO of Amicus Therapeutics. "In the months ahead in 2008, we will be focused on advancing the global regulatory plan for Amigal Phase 3 development, evaluating opportunities for additional clinical studies in Gaucher and Pompe disease, as well as on identifying new therapeutic areas for applying our pharmacological chaperone technology platform."

Program Advancements

Fabry Disease:

Amigal(TM) (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. In March, clinical investiga
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... received a $451,781 Air Force Office of Scientific Research ... and nano-scale level that will provide clues for predicting ... and Aerospace Engineering, said the new technology and process ... of an aircraft,s wing., "We,ll be able to determine ... at it on this scale," Huang said. "Certain patterns ...
(Date:10/17/2014)... SAN DIEGO and HILDEN, ...   , Translational research ... new capabilities being presented at the American Society ... Volume of 250,000-plus DNA samples linked to Ingenuity ... superior depth for genomic analysis  Ingenuity ...
(Date:10/17/2014)... October 17, 2014 Bioquell, provider ... upon by health facilities around the world to ... being treated. Among the many places the hydrogen ... Health Presbyterian Hospital Dallas and at the National ... vapor-producing robots have been utilized to decontaminate patient ...
(Date:10/17/2014)... 17, 2014 The global SWIR market ... analysis and forecast of revenue. This market is valued ... reach $97.9 million by 2019, at a CAGR of ... TOC of the global SWIR market report, to get ... provides a glimpse of the segmentation of the market, ...
Breaking Biology Technology:UT Arlington project to detect possible damages in aircraft parts early in process 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 3QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 4QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 5QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 6Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 2The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 3
... Therapeutics Corporation today,announced that Blake M. Paterson M.D., ... in Bioscience Award from the Greater Baltimore Council.,Dr. ... nominees,submitted by businesses, bioscience advocates, higher education,institutions and ... Dr. Paterson has received this award from the ...
... March 18 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Lehman Brothers Global Healthcare Conference in Miami, will ... EDT. Kevin Hrusovsky, President and CEO of,Caliper, will ... The live,webcast can be accessed at, http://cc.talkpoint.com/LEHM002/031808a_jw/default.asp?entity=Caliper . ...
... Three biotech CEOs and,the president of one ... by the Greater Baltimore Committee as winners of ... the 2008 Greater Baltimore Region Bioscience Awards are:, ... E. Askew, President & CEO, CSA,Medical, Inc. Askew,s ...
Cached Biology Technology:Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award 2Three CEOs and University President Named Winners of Greater Baltimore Committee's 2008 Baltimore Region Bioscience Awards 2
(Date:10/15/2014)... pneumonia in female mice to an enzyme activated by ... more resistant to respiratory infections than males. Now, an ... to bacterial pneumonia in female mice is linked to ... show that this enzyme is ultimately activated by the ... team, lead by Professor Lester Kobzik at the Harvard ...
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... issues, 100 percent fruit and vegetable juices do help reduce ... conclusion is the result of a European study designed to ... significant role in reducing risk for both cancer and cardiovascular ... are comparable in their ability to reduce risk compared to ...
... created from poultry feathers may add value to ... environmental problem of plastic waste. , According to ... million tons of non-biodegradable plastic waste ends up ... of biological systems engineering at Virginia Tech, is ...
... to process information more chaotically than has long been ... by scientists at the University of Bonn. The passing ... they show, occur exclusively at the synapses, i.e. the ... that the neurons release their chemical messengers along the ...
Cached Biology News:100 percent juices found as beneficial to health as fruits and vegetables 2Researcher examines polymers created with poultry feathers 2Brain works more chaotically than previously thought 2Brain works more chaotically than previously thought 3